NEW INDICATION APPLICATION FOR SACITUZUMAB TIRUMOTECAN (SAC-TMT) IN COMBINATION WITH PEMBROLIZUMAB AS FIRST-LINE TREATMENT FOR PD-L1-NEGATIVE NON-SQUAMOUS NSCLC ACCEPTED FOR REVIEW BY NMPA

Reuters · 2d ago

Please log in to view news